Vital Therapies (VTL) Earns News Sentiment Rating of 0.10
Press coverage about Vital Therapies (NASDAQ:VTL) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vital Therapies earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.6863024373643 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Edited Transcript of VTL earnings conference call or presentation 3-Aug-17 8:30pm GMT (finance.yahoo.com)
- Vital Therapies Announces Second Quarter 2017 Financial Results (finance.yahoo.com)
- Zacks: Analysts Expect Vital Therapies, Inc. (VTL) to Post -$0.31 EPS (americanbankingnews.com)
- Vital Therapies, Inc. (NASDAQ:VTL) Issues Quarterly Earnings Results (americanbankingnews.com)
A number of research firms have weighed in on VTL. Zacks Investment Research raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a research note on Wednesday, May 10th. Raymond James Financial, Inc. began coverage on shares of Vital Therapies in a research note on Thursday, May 18th. They issued an “outperform” rating and a $6.00 price objective on the stock. Finally, ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $8.00.
Vital Therapies (NASDAQ VTL) traded down 2.459% on Tuesday, hitting $2.975. 47,396 shares of the company’s stock were exchanged. The stock’s market cap is $125.57 million. The firm has a 50 day moving average price of $2.89 and a 200-day moving average price of $3.71. Vital Therapies has a 52-week low of $2.25 and a 52-week high of $6.63.
Vital Therapies (NASDAQ:VTL) last released its earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.01. During the same quarter in the previous year, the company earned ($0.30) earnings per share. Analysts predict that Vital Therapies will post ($1.41) earnings per share for the current fiscal year.
In other news, Director Muneer A. Satter acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The shares were bought at an average cost of $3.19 per share, with a total value of $31,900.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Muneer A. Satter acquired 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The shares were purchased at an average cost of $3.07 per share, for a total transaction of $61,400.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 108,400 shares of company stock worth $338,153 over the last three months. 32.60% of the stock is currently owned by insiders.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.